The Role of Immune and Inflammatory Mechanisms in ALS

Overview

Journal Curr Mol Med

Publisher Bentham Science Publishers

Specialty Molecular Biology

Date 2011 Mar 8

PMID 21375489

Citations 120

Authors

P A McCombe

R D Henderson

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disease. The cause is unknown, but genetic abnormalities have been identified in subjects with familial ALS and also in subjects with sporadic ALS. Environmental factors such as occupational exposure have been shown to be risk factors for the development of ALS. Patients differ in their clinical features and differ in the clinical course of disease. Immune abnormalities have been found in the central nervous system by pathological studies and also in the blood and CSF of subjects with ALS. Inflammation and immune abnormalities are also found in animals with a model of ALS due to mutations in the SOD1 gene. Previously it has been considered that immune abnormalities might contribute to the pathogenesis of disease. However more recently it has become apparent that an immune response can occur as a response to damage to the nervous system and this can be protective.

Citing Articles

Increased risk of ischemic stroke in amyotrophic lateral sclerosis: a nationwide cohort study in South Korea.

Kwon S, Kim B, Han K, Jung W, Cho E, Shin D Neurol Sci. 2025; .

PMID: 40048117 DOI: 10.1007/s10072-025-08074-1.

Whole-genome bisulfite sequencing of cell-free DNA unveils age-dependent and ALS-associated methylation alterations.

Jin Y, Conneely K, Ma W, Naviaux R, Siddique T, Allen E Cell Biosci. 2025; 15(1):26.

PMID: 39980027 PMC: 11843967. DOI: 10.1186/s13578-025-01366-1.

Nutritional and Microbiota-Based Approaches in Amyotrophic Lateral Sclerosis: From Prevention to Treatment.

Cuffaro F, Lamminpaa I, Niccolai E, Amedei A Nutrients. 2025; 17(1.

PMID: 39796536 PMC: 11722677. DOI: 10.3390/nu17010102.

Tracing ALS Degeneration: Insights from Spinal Cord and Cortex Transcriptomes.

Sneha N, Dharshini S, Taguchi Y, Gromiha M Genes (Basel). 2024; 15(11).

PMID: 39596631 PMC: 11593627. DOI: 10.3390/genes15111431.

Gut microbiota immune cross-talk in amyotrophic lateral sclerosis.

Kaul M, Mukherjee D, Weiner H, Cox L Neurotherapeutics. 2024; 21(6):e00469.

PMID: 39510899 PMC: 11585889. DOI: 10.1016/j.neurot.2024.e00469.

References

Beghi E, Chio A, Couratier P, Esteban J, Hardiman O, Logroscino G . The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2010; 12(1):1-10. PMC: 3513399. DOI: 10.3109/17482968.2010.502940. View

Mills C, Kincaid K, Alt J, Heilman M, Hill A . M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000; 164(12):6166-73. DOI: 10.4049/jimmunol.164.12.6166. View

Heiman-Patterson T, Sher R, Blankenhorn E, Alexander G, Deitch J, Kunst C . Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler. 2011; 12(2):79-86. DOI: 10.3109/17482968.2010.550626. View

McCombe P, Greer J, Mackay I . Sexual dimorphism in autoimmune disease. Curr Mol Med. 2009; 9(9):1058-79. DOI: 10.2174/156652409789839116. View

Banerjee R, Mosley R, Reynolds A, Dhar A, Jackson-Lewis V, Gordon P . Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One. 2008; 3(7):e2740. PMC: 2481277. DOI: 10.1371/journal.pone.0002740. View

Werdelin L, Boysen G, Jensen T, Mogensen P . Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 1990; 82(2):132-4. DOI: 10.1111/j.1600-0404.1990.tb01602.x. View

Sutedja N, Veldink J, Fischer K, Kromhout H, Wokke J, Huisman M . Lifetime occupation, education, smoking, and risk of ALS. Neurology. 2007; 69(15):1508-14. DOI: 10.1212/01.wnl.0000277463.87361.8c. View

Rose N, Bona C . Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today. 1993; 14(9):426-30. DOI: 10.1016/0167-5699(93)90244-F. View

Smith S, Miller R, Murphy J, Ringel S . Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci. 1994; 124 Suppl:84-7. DOI: 10.1016/0022-510x(94)90188-0. View

10.

Lincecum J, Vieira F, Wang M, Thompson K, De Zutter G, Kidd J . From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet. 2010; 42(5):392-9. DOI: 10.1038/ng.557. View

11.

Heiman-Patterson T, Deitch J, Blankenhorn E, Erwin K, Perreault M, Alexander B . Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci. 2005; 236(1-2):1-7. DOI: 10.1016/j.jns.2005.02.006. View

12.

Kosloski L, Ha D, Hutter J, Stone D, Pichler M, Reynolds A . Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem. 2010; 114(5):1261-76. PMC: 2923270. DOI: 10.1111/j.1471-4159.2010.06834.x. View

13.

Vazquez M, Ketzoian C, Legnani C, Rega I, Sanchez N, Perna A . Incidence and prevalence of amyotrophic lateral sclerosis in Uruguay: a population-based study. Neuroepidemiology. 2008; 30(2):105-11. DOI: 10.1159/000120023. View

14.

Zhang R, Gascon R, Miller R, Gelinas D, Mass J, Hadlock K . Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2005; 159(1-2):215-24. DOI: 10.1016/j.jneuroim.2004.10.009. View

15.

Sanagi T, Yuasa S, Nakamura Y, Suzuki E, Aoki M, Warita H . Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J Neurosci Res. 2010; 88(12):2736-46. DOI: 10.1002/jnr.22424. View

16.

. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors. J Neurol Sci. 1995; 129 Suppl:1-10. View

17.

Schwartz M, Moalem G . Beneficial immune activity after CNS injury: prospects for vaccination. J Neuroimmunol. 2001; 113(2):185-92. DOI: 10.1016/s0165-5728(00)00447-1. View

18.

Keller A, Gravel M, Kriz J . Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol. 2010; 228(1):69-79. DOI: 10.1016/j.expneurol.2010.12.010. View

19.

Galimberti D, Scarpini E . Inflammation and oxidative damage in Alzheimer's disease: friend or foe?. Front Biosci (Schol Ed). 2011; 3(1):252-66. DOI: 10.2741/s149. View

20.

Turner M, Cagnin A, Turkheimer F, Miller C, Shaw C, Brooks D . Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004; 15(3):601-9. DOI: 10.1016/j.nbd.2003.12.012. View